

Francesco Giganti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/104701/publications.pdf>

Version: 2024-02-01

104
papers

5,895
citations

156536

32
h-index

87275

74
g-index

108
all docs

108
docs citations

108
times ranked

6353
citing authors

#	ARTICLE	IF	CITATIONS
1	Promoting the use of the PI-QUAL score for prostate MRI quality: results from the ESOR Nicholas Courtsoyiannis teaching fellowship. <i>European Radiology</i> , 2023, 33, 461-471.	2.3	13
2	Three-dimensional Magnetic Resonance Imaging-based Printed Models of Prostate Anatomy and Targeted Biopsy-proven Index Tumor to Facilitate Patient-tailored Radical Prostatectomy: A Feasibility Study. <i>European Urology Oncology</i> , 2022, 5, 357-361.	2.6	7
3	Inter-reader agreement of the PI-QUAL score for prostate MRI quality in the NeuroSAFE PROOF trial. <i>European Radiology</i> , 2022, 32, 879-889.	2.3	32
4	Tumour growth rates of prostate cancer during active surveillance: is there a difference between MRI-visible low and intermediate-risk disease?. <i>British Journal of Radiology</i> , 2022, 95, 20210321.	1.0	5
5	Prostate MRI quality: a critical review of the last 5 years and the role of the PI-QUAL score. <i>British Journal of Radiology</i> , 2022, 95, 20210415.	1.0	22
6	Is perfect the enemy of good? Weighing the evidence for biparametric MRI in prostate cancer. <i>British Journal of Radiology</i> , 2022, 95, 20210840.	1.0	1
7	Relationship of prostate cancer topography and tumour conspicuity on multiparametric magnetic resonance imaging: a protocol for a systematic review and meta-analysis. <i>BMJ Open</i> , 2022, 12, e050376.	0.8	2
8	Diagnostic Accuracy of Abbreviated Bi-Parametric MRI (a-bpMRI) for Prostate Cancer Detection and Screening: A Multi-Reader Study. <i>Diagnostics</i> , 2022, 12, 231.	1.3	5
9	Magnetic Resonance Imaging and Targeted Biopsies Compared to Transperineal Mapping Biopsies Before Focal Ablation in Localised and Metastatic Recurrent Prostate Cancer After Radiotherapy. <i>European Urology</i> , 2022, 81, 598-605.	0.9	9
10	Magnetic Resonance Imaging-guided Active Surveillance of Prostate Cancer: Time to Say Goodbye to Protocol-based Biopsies. <i>European Urology Open Science</i> , 2022, 38, 40-43.	0.2	5
11	Negative mpMRI Rules Out Extra-Prostatic Extension in Prostate Cancer before Robot-Assisted Radical Prostatectomy. <i>Diagnostics</i> , 2022, 12, 1057.	1.3	11
12	Geographic Variability, Time Trends and Association of Preoperative Magnetic Resonance Imaging with Surgical Outcomes for Elderly United States Men with Prostate Cancer: A Surveillance, Epidemiology, and End Results-Medicare Analysis. <i>Journal of Urology</i> , 2022, 208, 609-617.	0.2	6
13	Detection of Significant Prostate Cancer Using Target Saturation in Transperineal Magnetic Resonance Imaging/Transrectal Ultrasonography-fusion Biopsy. <i>European Urology Focus</i> , 2021, 7, 1300-1307.	1.6	44
14	Standardized Magnetic Resonance Imaging Reporting Using the Prostate Cancer Radiological Estimation of Change in Sequential Evaluation Criteria and Magnetic Resonance Imaging/Transrectal Ultrasound Fusion with Transperineal Saturation Biopsy to Select Men on Active Surveillance. <i>European Urology Focus</i> , 2021, 7, 102-110.	1.6	28
15	Update on Multiparametric Prostate MRI During Active Surveillance: Current and Future Trends and Role of the PRECISE Recommendations. <i>American Journal of Roentgenology</i> , 2021, 216, 943-951.	1.0	18
16	Natural history of prostate cancer on active surveillance: stratification by MRI using the PRECISE recommendations in a UK cohort. <i>European Radiology</i> , 2021, 31, 1644-1655.	2.3	37
17	Imaging quality and prostate MR: it is time to improve. <i>British Journal of Radiology</i> , 2021, 94, 20200934.	1.0	12
18	PI-RADS Version 2.1: A Critical Review, From the <i>AJR</i> Special Series on Radiology Reporting and Data Systems. <i>American Journal of Roentgenology</i> , 2021, 216, 20-32.	1.0	36

#	ARTICLE	IF	CITATIONS
19	False Positive Multiparametric Magnetic Resonance Imaging Phenotypes in the Biopsy-naïve Prostate: Are They Distinct from Significant Cancer-associated Lesions? Lessons from PROMIS. <i>European Urology</i> , 2021, 79, 20-29.	0.9	13
20	Prostate Cancer Undetected by mpMRI: Tumor Conspicuity is Reliant Upon Optimal Scan Timing and Quality. <i>Urology</i> , 2021, 148, 316-317.	0.5	1
21	Mixed acinar and macrocystic ductal prostatic adenocarcinoma. <i>Lancet Oncology</i> , The, 2021, 22, e37.	5.1	1
22	Synthesizing VERDICT Maps from Standard DWI Data Using GANs. <i>Lecture Notes in Computer Science</i> , 2021, , 58-67.	1.0	1
23	The Importance of Being PRECISE in Prostate Magnetic Resonance Imaging and Active Surveillance. <i>European Urology</i> , 2021, 79, 560-563.	0.9	7
24	Standardisation of prostate multiparametric MRI across a hospital network: a London experience. <i>Insights Into Imaging</i> , 2021, 12, 52.	1.6	11
25	Letâ€™s Follow the Golden Mean: Using Magnetic Resonance Imaging to Determine the Need for Biopsy in Men on Active Surveillance. <i>European Urology Oncology</i> , 2021, 4, 235-236.	2.6	1
26	Morphological Change Forecasting For Prostate Glands Using Feature-Based Registration And Kernel Density Extrapolation. , 2021, , .		1
27	Followup of Men with PI-RADS TM 4 or 5 Abnormality on Prostate Magnetic Resonance Imaging and Nonmalignant Pathological Findings on Initial Targeted Prostate Biopsy. Letter.. <i>Journal of Urology</i> , 2021, 205, 1526-1528.	0.2	0
28	Understanding PI-QUAL for prostate MRI quality: a practical primer for radiologists. <i>Insights Into Imaging</i> , 2021, 12, 59.	1.6	43
29	Mapping PSA density to outcome of MRI-based active surveillance for prostate cancer through joint longitudinal-survival models. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 1028-1031.	2.0	10
30	Update from the ReIMAGINE Prostate Cancer Screening Study NCT04063566: Inviting Men for Prostate Cancer Screening Using Magnetic Resonance Imaging. <i>European Urology Focus</i> , 2021, 7, 503-505.	1.6	5
31	MRI and targeted biopsies compared to transperineal mapping biopsies for targeted ablation in recurrent prostate cancer after radiotherapy: Primary outcomes of the FORECAST trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 5009-5009.	0.8	1
32	Prostate minimally invasive procedures: complications and normal vs. abnormal findings on multiparametric magnetic resonance imaging (mpMRI). <i>Abdominal Radiology</i> , 2021, 46, 4388-4400.	1.0	6
33	MRI Targeted Prostate Biopsy Techniques: <i>AJR</i> Expert Panel Narrative Review. <i>American Journal of Roentgenology</i> , 2021, 217, 1263-1281.	1.0	7
34	Mapping Contemporary Biopsy Zones to Traditional Prostatic Anatomy: The Key to Understanding Relationships Between Prostate Cancer Topography, Magnetic Resonance Imaging Conspicuity, and Clinical Risk. <i>European Urology</i> , 2021, 80, 263-265.	0.9	3
35	ReIMAGINE Prostate Cancer Screening Study: protocol for a single-centre feasibility study inviting men for prostate cancer screening using MRI. <i>BMJ Open</i> , 2021, 11, e048144.	0.8	10
36	Unsupervised Domain Adaptation with Semantic Consistency Across Heterogeneous Modalities for MRI Prostate Lesion Segmentation. <i>Lecture Notes in Computer Science</i> , 2021, , 90-100.	1.0	2

#	ARTICLE	IF	CITATIONS
37	Multiparametric prostate MRI quality assessment using a semi-automated PI-QUAL software program. <i>European Radiology Experimental</i> , 2021, 5, 48.	1.7	17
38	Progress in Prostate MRI Quality. <i>Academic Radiology</i> , 2021, , .	1.3	2
39	Gastric cancer and image-derived quantitative parameters: Part 2â€™a critical review of DCE-MRI and 18F-FDG PET/CT findings. <i>European Radiology</i> , 2020, 30, 247-260.	2.3	33
40	Multiparametric MRI for prostate cancer diagnosis: current status and future directions. <i>Nature Reviews Urology</i> , 2020, 17, 41-61.	1.9	207
41	Esophagus and Stomach. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2020, 28, 1-15.	0.6	8
42	Interobserver reproducibility of the PRECISE scoring system for prostate MRI on active surveillance: results from a two-centre pilot study. <i>European Radiology</i> , 2020, 30, 2082-2090.	2.3	20
43	Magnetic Resonance Imaging Should Be Used in the Active Surveillance of Patients with Localised Prostate Cancer. <i>European Urology</i> , 2020, 77, 318-319.	0.9	10
44	DWI and PRECISE criteria in men on active surveillance for prostate cancer: A multicentre preliminary experience of different ADC calculations. <i>Magnetic Resonance Imaging</i> , 2020, 67, 50-58.	1.0	14
45	Prostate Imaging Quality (PI-QUAL): A New Quality Control Scoring System for Multiparametric Magnetic Resonance Imaging of the Prostate from the PRECISION trial. <i>European Urology Oncology</i> , 2020, 3, 615-619.	2.6	155
46	Reply to Carissa E. Chu, Peter E. Lonergan, and Peter R. Carrollâ€™s Letter to the Editor re: Vasilis Stavrinos, Francesco Giganti, Bruce Trock, et al. Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large Cohort Study. <i>Eur Urol</i> 2020;78:443â€™51. <i>European Urology</i> , 2020, 78, e112-e113.	0.9	0
47	Reply to Francesco Montorsi, Giorgio Gandaglia, Nicola Fossati, Andrea Salonia, and Alberto Brigantiâ€™s Letter to the Editor re: Vasilis Stavrinos, Francesco Giganti, Bruce Trock, et al. Five-year Outcomes of Magnetic Resonance Imagingâ€™based Active Surveillance for Prostate Cancer: A Large Cohort Study. <i>Eur Urol</i> 2020;78:443â€™51. <i>European Urology</i> , 2020, 78, e166.	0.9	0
48	Prostate cancer measurements on serial MRI during active surveillance: itâ€™s time to be PRECISE. <i>British Journal of Radiology</i> , 2020, 93, 20200819.	1.0	11
49	ESUR/ESUI consensus statements on multi-parametric MRI for the detection of clinically significant prostate cancer: quality requirements for image acquisition, interpretation and radiologistsâ€™ training. <i>European Radiology</i> , 2020, 30, 5404-5416.	2.3	185
50	The Role of Percentage of Prostate-specific Antigen Reduction After Focal Therapy Using High-intensity Focused Ultrasound for Primary Localised Prostate Cancer. Results from a Large Multi-institutional Series. <i>European Urology</i> , 2020, 78, 155-160.	0.9	18
51	Factors Influencing Variability in the Performance of Multiparametric Magnetic Resonance Imaging in Detecting Clinically Significant Prostate Cancer: A Systematic Literature Review. <i>European Urology Oncology</i> , 2020, 3, 145-167.	2.6	75
52	Focus on the Quality of Prostate Multiparametric Magnetic Resonance Imaging: Synopsis of the ESUR/ESUI Recommendations on Quality Assessment and Interpretation of Images and Radiologistsâ€™ Training. <i>European Urology</i> , 2020, 78, 483-485.	0.9	27
53	Five-year Outcomes of Magnetic Resonance Imagingâ€™based Active Surveillance for Prostate Cancer: A Large Cohort Study. <i>European Urology</i> , 2020, 78, 443-451.	0.9	94
54	Harnessing Uncertainty in Domain Adaptation for MRI Prostate Lesion Segmentation. <i>Lecture Notes in Computer Science</i> , 2020, , 510-520.	1.0	17

#	ARTICLE	IF	CITATIONS
55	ESUR/ESUI consensus statements on multi-parametric MRI for the detection of clinically significant prostate cancer: quality requirements for image acquisition, interpretation and radiologists' training. , 2020, 30, 5404.		1
56	The role of additional standard biopsy in the MRI-targeted biopsy era. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2020, 72, 637-639.	3.9	12
57	Active surveillance for low-risk prostate cancer " in pursuit of a standardized protocol. <i>Central European Journal of Urology</i> , 2020, 73, 123-126.	0.2	1
58	Longitudinal Image Registration with Temporal-Order and Subject-Specificity Discrimination. <i>Lecture Notes in Computer Science</i> , 2020, , 243-252.	1.0	5
59	Re: Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?. <i>Journal of Urology</i> , 2020, 204, 1065-1066.	0.2	0
60	MRI in active surveillance: a critical review. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 5-15.	2.0	36
61	Prediction of significant prostate cancer in biopsy-naïve men: Validation of a novel risk model combining MRI and clinical parameters and comparison to an ERSPC risk calculator and PI-RADS. <i>PLoS ONE</i> , 2019, 14, e0221350.	1.1	13
62	Magnetic Resonance Imaging-targeted Biopsy Versus Systematic Biopsy in the Detection of Prostate Cancer: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2019, 76, 284-303.	0.9	153
63	Machine learning classifiers can predict Gleason pattern 4 prostate cancer with greater accuracy than experienced radiologists. <i>European Radiology</i> , 2019, 29, 4754-4764.	2.3	55
64	The Evolution of MRI of the Prostate: The Past, the Present, and the Future. <i>American Journal of Roentgenology</i> , 2019, 213, 384-396.	1.0	39
65	VERDICT MRI for Prostate Cancer: Intracellular Volume Fraction versus Apparent Diffusion Coefficient. <i>Radiology</i> , 2019, 291, 391-397.	3.6	52
66	Prostate cancer treated with irreversible electroporation: MRI-based volumetric analysis and oncological outcome. <i>Magnetic Resonance Imaging</i> , 2019, 58, 143-147.	1.0	13
67	Medium-term oncological outcomes in a large cohort of men treated with either focal or hemi-ablative using high-intensity focused ultrasonography for primary localized prostate cancer. <i>BJU International</i> , 2019, 124, 431-440.	1.3	93
68	MRI in early detection of prostate cancer. <i>Current Opinion in Urology</i> , 2019, 29, 563-568.	0.9	8
69	Simplified Luminal Water Imaging for the Detection of Prostate Cancer From Multiecho T ₂ MR Images. <i>Journal of Magnetic Resonance Imaging</i> , 2019, 50, 910-917.	1.9	16
70	Multi-parametric MRI zone-specific diagnostic model performance compared with experienced radiologists for detection of prostate cancer. <i>European Radiology</i> , 2019, 29, 4150-4159.	2.3	8
71	Sequential prostate MRI reporting in men on active surveillance: initial experience of a dedicated PRECISE software program. <i>Magnetic Resonance Imaging</i> , 2019, 57, 34-39.	1.0	13
72	Prostate cancer heterogeneity: texture analysis score based on multiple magnetic resonance imaging sequences for detection, stratification and selection of lesions at time of biopsy. <i>BJU International</i> , 2019, 124, 76-86.	1.3	18

#	ARTICLE	IF	CITATIONS
73	A Dedicated Prostate MRI Teaching Course Improves the Ability of the Urologist to Interpret Clinically Significant Prostate Cancer on Multiparametric MRI. <i>European Urology</i> , 2019, 75, 203-204.	0.9	16
74	Gastric cancer and imaging biomarkers: Part 1 – a critical review of DW-MRI and CE-MDCT findings. <i>European Radiology</i> , 2019, 29, 1743-1753.	2.3	40
75	Prostate Indeterminate Lesions on Magnetic Resonance Imaging – Biopsy Versus Surveillance: A Literature Review. <i>European Urology Focus</i> , 2019, 5, 799-806.	1.6	27
76	Is magnetic resonance imaging – targeted biopsy a useful addition to systematic confirmatory biopsy in men on active surveillance for low – risk prostate cancer? A systematic review and meta – analysis. <i>BJU International</i> , 2018, 122, 946-958.	1.3	73
77	Automatic Multi-Organ Segmentation on Abdominal CT With Dense V-Networks. <i>IEEE Transactions on Medical Imaging</i> , 2018, 37, 1822-1834.	5.4	436
78	National implementation of multi – parametric magnetic resonance imaging for prostate cancer detection – recommendations from a <sc>UK</sc> consensus meeting. <i>BJU International</i> , 2018, 122, 13-25.	1.3	106
79	MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. <i>New England Journal of Medicine</i> , 2018, 378, 1767-1777.	13.9	2,036
80	An update of pitfalls in prostate mpMRI: a practical approach through the lens of PI-RADS v. 2 guidelines. <i>Insights Into Imaging</i> , 2018, 9, 87-101.	1.6	69
81	Prostate cancer detection using quantitative T ₂ and T ₂ – weighted imaging: The effects of 5 – alpha – reductase inhibitors in men on active surveillance. <i>Journal of Magnetic Resonance Imaging</i> , 2018, 47, 1646-1653.	1.9	12
82	Magnetic resonance imaging in active surveillance – a modern approach. <i>Translational Andrology and Urology</i> , 2018, 7, 116-131.	0.6	11
83	The natural history of prostate cancer on MRI: lessons from an active surveillance cohort. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 556-563.	2.0	13
84	MRI in prostate cancer diagnosis: do we need to add standard sampling? A review of the last 5 years. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 473-487.	2.0	42
85	Can MRI Replace Biopsy in Men on Surveillance?. <i>Current Clinical Urology</i> , 2018, , 111-119.	0.0	0
86	Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer: The PRECISE Recommendations – A Report of a European School of Oncology Task Force. <i>European Urology</i> , 2017, 71, 648-655.	0.9	190
87	Oesophageal cancer staging: a minefield of measurements – <i>author's reply</i>. <i>British Journal of Radiology</i> , 2017, 90, 20170054.	1.0	4
88	Pre-treatment MDCT-based texture analysis for therapy response prediction in gastric cancer: Comparison with tumour regression grade at final histology. <i>European Journal of Radiology</i> , 2017, 90, 129-137.	1.2	55
89	Towards Image-Guided Pancreas and Biliary Endoscopy: Automatic Multi-organ Segmentation on Abdominal CT with Dense Dilated Networks. <i>Lecture Notes in Computer Science</i> , 2017, , 728-736.	1.0	28
90	MRI findings in men on active surveillance for prostate cancer: does dutasteride make MRI visible lesions less conspicuous? Results from a placebo-controlled, randomised clinical trial. <i>European Radiology</i> , 2017, 27, 4767-4774.	2.3	24

#	ARTICLE	IF	CITATIONS
91	The Effect of Dutasteride on Magnetic Resonance Imaging Defined Prostate Cancer: MAPPEDâ€”A Randomized, Placebo Controlled, Double-Blind Clinical Trial. <i>Journal of Urology</i> , 2017, 197, 1006-1013.	0.2	19
92	Gastric cancer: texture analysis from multidetector computed tomography as a potential preoperative prognostic biomarker. <i>European Radiology</i> , 2017, 27, 1831-1839.	2.3	93
93	A critical comparison of techniques for MRI-targeted biopsy of the prostate. <i>Translational Andrology and Urology</i> , 2017, 6, 432-443.	0.6	53
94	Apparent diffusion coefficient by diffusion-weighted magnetic resonance imaging as a sole biomarker for staging and prognosis of gastric cancer. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2017, 29, 118-126.	0.7	17
95	Prognostic utility of diffusion-weighted MRI in oesophageal cancer: is apparent diffusion coefficient a potential marker of tumour aggressiveness?. <i>Radiologia Medica</i> , 2016, 121, 173-180.	4.7	22
96	Prospective comparison of MR with diffusion-weighted imaging, endoscopic ultrasound, MDCT and positron emission tomography-CT in the pre-operative staging of oesophageal cancer: results from a pilot study. <i>British Journal of Radiology</i> , 2016, 89, 20160087.	1.0	47
97	Preoperative locoregional staging of gastric cancer: is there a place for magnetic resonance imaging? Prospective comparison with EUS and multidetector computed tomography. <i>Gastric Cancer</i> , 2016, 19, 216-225.	2.7	44
98	Apparent diffusion coefficient in the evaluation of side-specific extracapsular extension in prostate cancer: Development and external validation of a nomogram of clinical use. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 291.e9-291.e17.	0.8	26
99	New Insights in Abdominal Pain in Paroxysmal Nocturnal Hemoglobinuria (PNH): A MRI Study. <i>PLoS ONE</i> , 2015, 10, e0122832.	1.1	8
100	Magnetic Resonance Imaging in Active Surveillance of Prostate Cancer: A Systematic Review. <i>European Urology</i> , 2015, 67, 627-636.	0.9	284
101	Apparent Diffusion Coefficient Value and Ratio as Noninvasive Potential Biomarkers to Predict Prostate Cancer Grading: Comparison With Prostate Biopsy and Radical Prostatectomy Specimen. <i>American Journal of Roentgenology</i> , 2015, 204, 550-557.	1.0	78
102	Prognostic Role of Diffusion-weighted MR Imaging for Resectable Gastric Cancer. <i>Radiology</i> , 2015, 276, 444-452.	3.6	30
103	Response to chemotherapy in gastric adenocarcinoma with diffusion-weighted MRI and ¹⁸ F-FDG-PET/CT: Correlation of apparent diffusion coefficient and partial volume corrected standardized uptake value with histological tumor regression grade. <i>Journal of Magnetic Resonance Imaging</i> , 2014, 40, 1147-1157.	1.9	49
104	Apparent diffusion coefficient modifications in assessing gastro-oesophageal cancer response to neoadjuvant treatment: comparison with tumour regression grade at histology. <i>European Radiology</i> , 2013, 23, 2165-2174.	2.3	94